Assess whether to resubmit, meet, or pause the program (c42758)

SITUATION A site-change that invalidates stability claims put disproportionate reporting signal workbook in front of pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / Pharmacovigilance close is to resubmit, meet, or from disproportionate reporting signal workbook, and the live options are To resubmit, meet,, Pause the program.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. A site-change that invalidates stability claims is noise around an already-controlled Pharmacovigilance process in a labeling team facing a boxed-warning debate, given disproportionate reporting signal workbook. 2. A site-change that invalidates stability claims is the event in disproportionate reporting signal workbook that forces To resubmit, meet, for pharmacovigilance medical reviewer under Pharma & Life Sciences. 3. Disproportionate reporting signal workbook shows a one-file miss after a site-change that invalidates stability claims, not a Pharmacovigilance program failure. 4. Disproportionate reporting signal workbook cannot decide to resubmit, meet, or yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after a site-change that invalidates stability claims). The follow-on Pharmacovigilance action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in disproportionate reporting signal workbook that a second reviewer can re-perform